{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:00:51Z","timestamp":1790258451564,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100019405","name":"Kentucky IDeA Networks of Biomedical Research Excellence","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019405","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40261-026-01577-5","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T16:08:22Z","timestamp":1786550902000},"page":"1175-1185","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Modeling Cancer Outcomes and Economic Impact of the Anti-PD-1\/PD-L1 Immunotherapy in the Gulf: United Arab Emirates, Oman, and Kuwait"],"prefix":"10.1007","volume":"46","author":[{"given":"Humaid O.","family":"Al-Shamsi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Farghaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammar","family":"Abdaljalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulwahab","family":"Al-Tourah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9705-4896","authenticated-orcid":false,"given":"Chana","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8664-668X","authenticated-orcid":false,"given":"Youmna","family":"Bassil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghadah","family":"Albassam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Nimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Naroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"El-Badry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rony","family":"Akel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"1577_CR1","unstructured":"UAE-National Cancer Registry. Cancer incidence in United Arab Emirates [Internet]. 2021. www.mohap.gov.ae."},{"key":"1577_CR2","unstructured":"International Agency for Research on Cancer (IARC). Globocan 2022 Kuwait cancer factsheet [Internet]. 2022. https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/414-kuwait-fact-sheet.pdf. Accessed 26 Mar 2024."},{"key":"1577_CR3","unstructured":"State of Kuwait Central Statistical Bureau. Annual bulletin for vital statistics: births and deaths 2022 [Internet]. 2022. https:\/\/www.csb.gov.kw\/Pages\/Statistics_en?ID=10&ParentCatID=1. Accessed 26 Mar 2024."},{"key":"1577_CR4","unstructured":"International Agency for Research on Cancer (IARC). Globocan 2022 Oman cancer factsheet [Internet]. 2022. https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/512-oman-fact-sheet.pdf. Accessed 26 Mar 2024."},{"key":"1577_CR5","volume-title":"The epidemiology of cancer in the United Arab Emirates: a systematic review. Medicine (United States)","author":"H Radwan","year":"2018","unstructured":"Radwan H, Hasan H, Ballout RA, Rizk R. The epidemiology of cancer in the United Arab Emirates: a systematic review. Medicine (United States), vol. 97. Lippincott Williams and Wilkins; 2018."},{"key":"1577_CR6","unstructured":"Elbasmi A, Al-Asfour A, Al-Nesf Y, Al-Awadi A. Cancer in Kuwait: magnitude of the problem. Gulf J Oncolog. 2010;(8):7\u201314."},{"key":"1577_CR7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.5001\/omj.2019.55","volume":"34","author":"JA Al-Lawati","year":"1996","unstructured":"Al-Lawati JA, Al-Zakwani I, Fadhil I, Al-Bahrani BJ. Cancer incidence in Oman (1996\u20132015). Oman Med J. 1996;34:271\u20133.","journal-title":"Oman Med J"},{"key":"1577_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-16-7945-2_12","volume-title":"Cancer in the Arab world","author":"I Mehdi","year":"2022","unstructured":"Mehdi I, Al Farsi AA, Al Bahrani B, Al-Raisi SS (2022) General oncology care in Oman. In: Al-Shamsi HO, Abu-Gheida IH, Iqbal F, Al-Awadhi A, editors. Cancer in the Arab world. Springer, Singapore. https:\/\/doi.org\/10.1007\/978-981-16-7945-2_12."},{"key":"1577_CR9","unstructured":"World Health Organisation (WHO). WHO country cooperation strategy at a glance: Kuwait. 2017. https:\/\/policycommons.net\/artifacts\/545749\/who-country-cooperation-strategy-at-a-glance\/1523335\/. Accessed 21 Mar 2024."},{"key":"1577_CR10","unstructured":"InterNations. Health insurance and healthcare in the UAE explained. [Internet]. 2019. https:\/\/www.internations.org\/uae-expats\/guide\/healthcare. Accessed 20 Mar 2024."},{"key":"1577_CR11","unstructured":"United Arab Emirates Ministry of Health and Prevention. UAE statistical annual report 2020 [Internet]. 2022. https:\/\/mohap.gov.ae\/assets\/download\/eb379300\/UAE%20Statistical%20Annual%20Report%202020.docx.aspx. Accessed 20 Mar 2024."},{"key":"1577_CR12","unstructured":"United Arab Emirates Ministry of Finance. Federal budget for fiscal year 2020 [Internet]. 2021. https:\/\/mofstg.moca.gov.ae\/federal-budget-2020-ar\/. Accessed 20 Mar 2024."},{"key":"1577_CR13","unstructured":"United Arab Emirates Ministry of Finance. Federal budget 2022 [Internet]. 2022. https:\/\/mof.gov.ae\/federal-budget-2022\/. Accessed 20 Mar 2024."},{"key":"1577_CR14","unstructured":"Kuwait Life Sciences Company. Kuwait health report 2019. 2019. https:\/\/www.scribd.com\/document\/454887556\/KLSC-BDU-Kuwait-Healthcare-Report-2019-vF-pdf. Accessed 21 Mar 2024."},{"key":"1577_CR15","unstructured":"State of Kuwait. Voluntary National Review 2019: Report on the implementation of the 2030 agenda to the United Nations high-level political forum on sustainable development [Internet]. New York: United Nations High-Level Political Forum on Sustainable Development; 2019. https:\/\/hlpf.un.org\/countries\/kuwait\/voluntary-national-review-2019. Accessed 20 Mar 2024."},{"key":"1577_CR16","unstructured":"Ministry of Health, Sultanate of Oman. Health vision 2050: the main document [Internet]. Muscat (Oman): Ministry of Health; 2014. https:\/\/www.oman.om\/docs\/default-source\/default-document-library\/health-vision-2050.pdf. Accessed 26 Mar 2024."},{"key":"1577_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-16-7945-2_19","volume-title":"Cancer in the Arab world","author":"IH Abu-Gheida","year":"2022","unstructured":"Abu-Gheida IH, Nijhawan N, Al-Awadhi A, Al-Shamsi HO (2022) General oncology care in the UAE. In: Al-Shamsi HO, Abu-Gheida IH, Iqbal F, Al-Awadhi A, editors. Cancer in the Arab world. Springer, Singapore. https:\/\/doi.org\/10.1007\/978-981-16-7945-2_19."},{"key":"1577_CR18","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3390\/clinpract12010016","volume":"12","author":"HO Al-Shamsi","year":"2022","unstructured":"Al-Shamsi HO, Abyad AM, Rafii S. A proposal for a national cancer control plan for the UAE: 2022\u20132026. Clin Pract. 2022;12:118\u201332.","journal-title":"Clin Pract"},{"issue":"10","key":"1577_CR19","doi-asserted-by":"publisher","first-page":"e1516","DOI":"10.1634\/theoncologist.2019-0701","volume":"25","author":"J Feliu","year":"2020","unstructured":"Feliu J, Jim\u00e9nez-Mun\u00e1rriz B, Basterretxea L, Paredero I, Llabr\u00e9s E, Antonio-Rebollo M, et al. Predicting chemotherapy toxicity in older patients with cancer: a multicenter prospective study. Oncologist. 2020;25(10):e1516\u201324.","journal-title":"Oncologist"},{"key":"1577_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1312","author":"SK Ramasubbu","year":"2021","unstructured":"Ramasubbu SK, Pasricha RK, Nath UK, Rawat VS, Das B. Quality of life and factors affecting it in adult cancer patients undergoing cancer chemotherapy in a tertiary care hospital. Cancer Rep. 2021. https:\/\/doi.org\/10.1002\/cnr2.1312.","journal-title":"Cancer Rep"},{"key":"1577_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1862-0","author":"G Clarke","year":"2015","unstructured":"Clarke G, Johnston S, Corrie P, Kuhn I, Barclay S. Withdrawal of anticancer therapy in advanced disease: a systematic literature review. BMC Cancer. 2015. https:\/\/doi.org\/10.1186\/s12885-015-1862-0.","journal-title":"BMC Cancer"},{"issue":"2 Pt A","key":"1577_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.molimm.2015.02.009","volume":"67","author":"A Swaika","year":"2015","unstructured":"Swaika A, Hammond WA, Joseph RW. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Mol Immunol. 2015;67(2 Pt A):4\u201317. https:\/\/doi.org\/10.1016\/j.molimm.2015.02.009.","journal-title":"Mol Immunol"},{"key":"1577_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.06.022","author":"B J\u00f6nsson","year":"1995","unstructured":"J\u00f6nsson B, Hofmarcher T, Lindgren P, Wilking N. The cost and burden of cancer in the European Union 1995\u20132014. Eur J Cancer. 1995. https:\/\/doi.org\/10.1016\/j.ejca.2016.06.022.","journal-title":"Eur J Cancer"},{"key":"1577_CR24","doi-asserted-by":"publisher","DOI":"10.1159\/000487084","author":"S Fischer","year":"2018","unstructured":"Fischer S, Hasan Ali O, Jochum W, Kluckert T, Flatz L, Siano M. Anti-PD-1 therapy leads to near-complete remission in a patient with metastatic basal cell carcinoma. Oncol Res Treat. 2018. https:\/\/doi.org\/10.1159\/000487084.","journal-title":"Oncol Res Treat"},{"issue":"8","key":"1577_CR25","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1002\/eji.202048994","volume":"51","author":"J Borst","year":"2021","unstructured":"Borst J, Busselaar J, Bosma DMT, Ossendorp F. Mechanism of action of PD-1 receptor\/ligand targeted cancer immunotherapy. Eur J Immunol. 2021;51(8):1911\u201320. https:\/\/doi.org\/10.1002\/eji.202048994.","journal-title":"Eur J Immunol"},{"issue":"1","key":"1577_CR26","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41598-020-58674-4.PMID:32034198;PMCID:PMC7005709","volume":"10","author":"L Sun","year":"2020","unstructured":"Sun L, Zhang L, Yu J, Zhang Y, Pang X, Ma C, et al. Clinical efficacy and safety of anti-PD-1\/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis. Sci Rep. 2020;10(1):2083. https:\/\/doi.org\/10.1038\/s41598-020-58674-4.PMID:32034198;PMCID:PMC7005709.","journal-title":"Sci Rep"},{"issue":"4","key":"1577_CR27","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1634\/theoncologist.2016-0419","volume":"22","author":"TF Nishijima","year":"2017","unstructured":"Nishijima TF, Shachar SS, Nyrop KA, Muss HB. Safety and tolerability of PD-1\/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis. Oncologist. 2017;22(4):470\u20139.","journal-title":"Oncologist"},{"issue":"4","key":"1577_CR28","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320\u201330.","journal-title":"N Engl J Med"},{"key":"1577_CR29","unstructured":"Cancer Research Institute. PD-1\/PD-L1 landscape [Internet]. 2020. https:\/\/www.cancerresearch.org\/scientists\/immuno-oncology-landscape\/pd-1-pd-l1-landscape#2019. Accessed 20 Mar 2024."},{"key":"1577_CR30","unstructured":"Straits Research. Oncology (cancer drugs) market: global industry analysis, size, share, growth, trends, and forecast [Internet]. Pune (India): Straits Research; 2026. Report Code: SRPH2078DR."},{"issue":"2","key":"1577_CR31","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2991\/jegh.k.210129.001","volume":"11","author":"MM Elamin","year":"2021","unstructured":"Elamin MM, Ibrahim AM, Al Zakwani W, et al. Health technology assessment in the Gulf Cooperation Council countries: A systematic review. J Epidemiol Glob Health. 2021;11(2):195\u2013205. https:\/\/doi.org\/10.2991\/jegh.k.210129.001.","journal-title":"J Epidemiol Glob Health"},{"key":"1577_CR32","doi-asserted-by":"crossref","unstructured":"Hughes R, Mountain G, Beyer A, Aguiar-Ib\u00e1\u00f1ez R, Chaker O, Tourret M, et al. Health impact projection of anti-PD-(L)1 inhibitors in 13 cancer indications in France. Poster EE532 presented at: ISPOR Europe 2022; 2022 Nov 6\u20139; Vienna, Austria. Value Health. 2022;25(12 Suppl):S.","DOI":"10.1016\/j.jval.2022.09.773"},{"key":"1577_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1133959","author":"L Costa","year":"2023","unstructured":"Costa L, Alexandre T, Mansinho A, Sousa R, Vieira C, Hughes R, et al. Health outcomes and budget impact projection of anti-PD-(L)1s in cancer care in Portugal. Front Public Health. 2023. https:\/\/doi.org\/10.3389\/fpubh.2023.1133959.","journal-title":"Front Public Health"},{"key":"1577_CR34","first-page":"1","volume-title":"What is sensitivity analysis. Consortium YHE","author":"M Taylor","year":"2009","unstructured":"Taylor M. What is sensitivity analysis. Consortium YHE. University of York; 2009. p. 1\u20138."},{"key":"1577_CR35","unstructured":"Fitch Solutions Forecast. United Arab Emirates pharmaceuticals report [Internet]. 2021. https:\/\/store.fitchsolutions.com\/pharmaceuticals-healthcare\/united-arab-emirates-pharmaceuticals-report. Accessed 20 May 2024."},{"key":"1577_CR36","unstructured":"Fitch Solutions Forecast. Kuwait pharmaceuticals report [Internet]. 2021. https:\/\/store.fitchsolutions.com\/pharmaceuticals-healthcare\/kuwait-pharmaceuticals-report. Accessed 20 May 2024."},{"key":"1577_CR37","unstructured":"Fitch Solutions Forecast. Oman pharmaceuticals report [Internet]. 2021. https:\/\/store.fitchsolutions.com\/pharmaceuticals-healthcare\/oman-pharmaceuticals-report. Accessed 20 May 2024."},{"issue":"7","key":"1577_CR38","doi-asserted-by":"publisher","first-page":"S371","DOI":"10.1016\/j.jval.2022.04.442","volume":"25","author":"U Akpamuk","year":"2022","unstructured":"Akpamuk U, Hughes R, Swales O, Oyan B, Kilickap S, Demirci U, et al. EE193 the health impact projection model of the PD-1\/PD-L1 inhibitor class in cancer care in Turkey. Value Health. 2022;25(7):S371. https:\/\/doi.org\/10.1016\/j.jval.2022.04.442.","journal-title":"Value Health"},{"key":"1577_CR39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.vhri.2023.05.005","volume":"37","author":"T Hofmarcher","year":"2023","unstructured":"Hofmarcher T, Manzano Garc\u00eda A, Wilking N, Lindgren P. The disease burden and economic burden of cancer in 9 countries in the Middle East and Africa. Value Health Reg Issues. 2023;37:81\u20137. https:\/\/doi.org\/10.1016\/j.vhri.2023.05.005.","journal-title":"Value Health Reg Issues"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01577-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01577-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01577-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:13:54Z","timestamp":1790255634000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01577-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1577"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01577-5","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors G.B., R.N., R.A., M.N., and O.B. are employees of MSD IDEA Middle East, a division of Merck Sharp & Dohme. H.S., M.F., A.A., A.A., C.S., and Y.B. declare that they have no conflicts of interest relevant to the contents of this manuscript.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Clinical trial data supporting efficacy are publicly available (CheckMate and KEYNOTE and IMPOWER trials). Cost data and other inputs are provided by the KOLs and are included in the Supplementary file. Market share assumptions remain proprietary to MSD.","order":5,"name":"Ethics","label":"Data Availability Statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors read and approved the final version of the manuscript and agree to be accountable for all aspects of the work. Conceptualization: Humaid O. Al-Shamsi, Mohamed Farghaly, Ammar Abdaljalil, Abdulwahab Altourah, Omar El-Badry, Rony Akel; methodology: Ghadah Albassam, Rami Nimer, Monika Naroz, Chana Saad, Youmna Bassil; formal analysis: Ghadah Albassam, Rami Nimer, Monika Naroz; data curation: Chana Saad, Youmna Bassil; writing\u2014original draft: Chana Saad, Youmna Bassil; writing\u2014review and editing: all authors; supervision: Ghadah Albassam, Rami Nimer, Monika Naroz","order":6,"name":"Ethics","label":"Authors' Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}